New ‘nomogram’ opens the door to improved personalized treatments, UCLA-led study shows UCLA Based on the study, researchers also created an online risk calculator that forecasts the probability of overall and progression-free survival in response to LuPSMA. Denise Heady | July 8, 2021 A new prognostic tool developed by researchers from the UCLA Jonsson Comprehensive Cancer Center and five other institutions helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy. The tool, described in a study published today in Lancet Oncology, analyzes a wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.